Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 5Esophageal Neoplasms 2Rectal Neoplasms 1Neoplasm Metastasis 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Adenocarcinoma 1

Interventions

Fluorouracil 219Leucovorin 202Oxaliplatin 192Irinotecan 150Bevacizumab 110Capecitabine 94Cetuximab 90Folfox protocol 54Chemotherapy, Adjuvant 36Panitumumab 30Colonoscopy 30pembrolizumab 23Drug Therapy 23Nivolumab 22Magnetic Resonance Spectroscopy 22Gemcitabine 21Blood Specimen Collection 20Radiotherapy 19Floxuridine 19Biopsy 19Neoadjuvant Therapy 18Laparoscopy 18IFL protocol 18Early Intervention, Educational 18Celecoxib 18Surveys and Questionnaires 17Surgical Procedures, Operative 16Immunohistochemistry 16Exercise 16trifluridine tipiracil drug combination 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × rilotumumab × Gastrointestinal × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡